Description
Release form
Tablets.
Packing
30 pcs.
Pharmacological action
Setegis has an alpha-adrenolytic effect. Blocking postsynaptic alpha1-adrenergic receptors of the smooth muscles of the triangle and neck of the bladder, proximal part of the urethra and prostate gland, reduces resistance to urine flow and normalizes urination in patients with BPH.
Indications
BPH, hypertension (as monotherapy or as part of combination therapy).
Contraindications
Hypersensitivity to terazosin or other alpha-blocking agents.
Use during pregnancy and lactation
During pregnancy and lactation, Setegis is used with great care, only after carefully comparing the relationship between the risk to the fetus or child and the positive effect for the mother.
Special instructions
After the first dose of the drug or in the first days of the course of treatment, the effect of the first dose may occur: a marked drop in blood pressure, mainly in the form of orthostatic hypotension with dizziness, a sense of uncertainty and fainting. Hypovolemia and limiting salt intake increase the risk of first-dose effects. The same phenomenon can be observed with the resumption of treatment after a few days off, therefore, treatment should be resumed using the initial dose.
Fainting occurs in about 1% of cases. In addition to the effect of the first dose, a too rapid increase in the dose and the simultaneous use of diuretics and other antihypertensive drugs can also cause fainting. Fainting is primarily due to severe orthostatic hypotension, but may be associated with tachycardia (120-160 beats / min). Orthostatic hypotension is most pronounced shortly after taking the drug, and the risk of fainting is highest between the 30th and 90th minutes. Getting up from a horizontal or sitting position, prolonged standing on feet, intense physical effort, high ambient temperature and the simultaneous use of alcohol can provoke dizziness, a feeling of insecurity, or even loss of consciousness. When a patient faints, one should lay down, give the legs an elevated position, and, if necessary, apply other measures of maintenance therapy.
When using Setegis in conjunction with diuretics and / or other antihypertensive agents, its dose is recommended to be reduced. In order to avoid the development of severe arterial hypotension, it is recommended to prescribe a concomitant drug in a low dose and at the same time carry out careful medical monitoring of the patient’s condition. The same precautions are needed when adding Setegis to current antihypertensive therapy. The initial dose of Setegis in these cases is also 1 mg.
In elderly patients, sensitivity to the hypotensive effect of terazosin may be increased.
With caution, the drug should be prescribed to patients with a predisposition to orthostatic hypotension, with coronary heart disease or other heart diseases, cerebrovascular accidents, grade III or IV hypertensive retinopathy, insulin-dependent diabetes mellitus, and impaired liver and kidney function.
Before starting treatment with Setegis, benign prostatic hyperplasia should be excluded malignant neoplasm of the prostate gland. When prescribing the drug to patients with benign prostatic hyperplasia, blood pressure should be monitored at the beginning of treatment and when the dose is changed during therapy. The effectiveness of Setegis in this disease is evaluated after 4-6 weeks of treatment with maintenance doses.
In case of lactose intolerance, its content in tablets should be taken into account (55 mg in each tablet 1 mg, 110 mg in each tablet 2 mg, 5 mg and 10 mg).
Use in pediatrics
Efficacy and safety of the drug in children have not been established.
Influence on the ability to drive vehicles and control mechanisms
At the beginning of treatment and when the dose of the drug is increased, patients are not recommended to engage in potentially dangerous activities that require increased attention and speed of psychomotor reactions (including driving vehicles) over a period of time, the duration of which is determined individually. In the future, the degree of restriction should be established depending on the individual response of the patient.
Composition
1 tab. contains terazosin 2 mg.
Dosage and administration of
Inside, Setegis tablets should be taken as a whole, without chewing, regardless of food intake.
BPH: the initial dose is 1 mg 1 time per day, the maintenance dose is 5-10 mg 1 time per day, the maximum daily dose is 20 mg.
Side effects
At the beginning of treatment, the “first-dose phenomenon” may occur – orthostatic hypotension up to the point of fainting. In addition, during treatment with Setegis, dizziness, headache, asthenia, drowsiness, palpitations, nausea, nasal congestion, visual impairment, peripheral edema, weight gain rarely occur – postural hypotension, tachycardia, hemodilution effects.
Drug Interactions
With the simultaneous use of Setegis with other antihypertensive drugs, it is possible to increase the antihypertensive effect.
Overdose
Symptoms: arterial hypotension, impaired movement coordination, fainting.
Treatment: The patient should be given a horizontal position with his legs raised. Conduct symptomatic therapy. There is no specific antidote. Hemodialysis is ineffective because terazosine is highly bound to plasma proteins. With the development of shock, it is necessary to increase the BCC with the subsequent introduction of vasopressor drugs.
Storage conditions
In dry, protected from light at a temperature not exceeding 20 ° C.
Active ingredient
Terazosin
Terms leave through pharmacies
In retseptu
lekarstvennaja form
tablets
